Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
The decision follows feedback from regulatory authorities after the completion of earlier-stage studies for the weight-management treatment, according to the company.
Amycretin, which targets two gut hormone receptors, GLP-1 and amylin, is a key candidate in the Danish drugmaker's efforts to develop new treatments beyond its highly successful obesity drug, Wegovy.
The company plans to initiate the Phase 3 program for adults with overweight or obesity during the first quarter of 2026.
The move comes after Novo Nordisk reported in January that an earlier trial of subcutaneous amycretin showed an estimated body weight loss of 22.0% at the highest dose over 36 weeks.
“We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3,” said Martin Lange, executive vice president for Development at Novo Nordisk.
“We are excited about the amycretin molecule, and this marks an important step forward.”
More from this issuer
Related coverage
Novo Nordisk on Friday appointed a new chairman and revamped its board, concluding a power struggle with its controlling shareholder, the Novo Nordisk Foundation.
Novo Nordisk said Friday it will not increase its offer to acquire U.S. drug developer Metsera Inc., ending a bidding war and citing a commitment to financial discipline.
Novo Nordisk on Wednesday narrowed its full-year financial outlook, citing slowing growth for its key obesity and diabetes drugs, as the company prepares for a board overhaul following a dispute with its controlling shareholder.
Novo Nordisk has made an unsolicited proposal to acquire drug developer Metsera Inc. in a deal worth up to $9 billion, as the Danish pharmaceutical giant continues its push to expand its portfolio of obesity and diabetes treatments.